ORIGINAL RESEARCH article

Front. Mol. Biosci., 02 October 2025

Sec. Molecular Diagnostics and Therapeutics

Volume 12 - 2025 | https://doi.org/10.3389/fmolb.2025.1662343

Clinical association and potential molecular mechanisms of neonatal sepsis and necrotizing enterocolitis

  • 1. Department of Neonatology, Children’s Hospital of Soochow University, Suzhou, China

  • 2. Suzhou Medical College, Soochow University, Suzhou, China

Abstract

Background:

Necrotizing enterocolitis (NEC) is a severe intestinal disease affecting premature infants, with mortality rates of 20%–30%. Clinical studies have shown that neonatal sepsis (NS) is an independent risk factor for NEC; however, the shared molecular mechanisms and diagnostic biomarkers between these two conditions remain poorly understood. This study aims to explore the shared molecular mechanisms underlying the association between NS and NEC and to identify potential diagnostic biomarkers.

Methods:

This study combines clinical cohort analysis with transcriptomic analysis. First, we enrolled 74 NEC infants and 74 gestational age/birth weight-matched controls from Children’s Hospital of Soochow University and quantified the association between NS and NEC using logistic regression analysis. Second, we jointly analyzed transcriptome data from NS (GSE25504) and NEC (GSE46619) datasets to screen for overlapping differentially expressed genes (DEGs) and constructed a protein-protein interaction (PPI) network to identify hub genes. Subsequently, the diagnostic efficacy of core genes was evaluated using independent validation cohorts (GSE297483 and GSE69686). Finally, a transcription factor-mRNA regulatory network was constructed using the TRRUST database to explore the underlying regulatory mechanisms.

Results:

Clinical association analysis showed a significantly increased risk of NEC in NS infants (OR = 3.02, P = 0.002). Infants in the NEC group had significantly higher systemic inflammatory markers and a higher incidence of sepsis (60.81% vs. 33.78%) compared to the control group. Mechanistic studies identified 70 co-directional overlapping DEGs, with 69 upregulated and 1 downregulated. These genes were significantly enriched in neutrophil chemotaxis and IL-17 signaling pathways (P < 0.05). Further investigation identified FPR1, S100A12, and CSF3R as potential biomarkers involved in immune response and inflammatory processes. External validation showed moderate diagnostic performance, with areas under the curve (AUCs) ranging from 0.723 to 0.813. Transcriptional regulation analysis revealed that transcription factors including SPI1, NFKB1, and JUN were identified as potential regulators of inflammatory genes.

Conclusion:

This study suggests that neonatal sepsis may serve as a risk factor for NEC development through shared inflammatory pathways involving FPR1, S100A12, and CSF3R. These genes demonstrated diagnostic potential across both conditions and appear to mediate inflammatory processes involving immune cell recruitment. While these findings suggest new directions for early identification in high-risk infants, further clinical validation is necessary to confirm therapeutic implications.

1 Introduction

Necrotizing enterocolitis (NEC) is a severe intestinal disease threatening premature infants, with pathogenesis linked to intestinal barrier damage, dysbiosis, and abnormal immune activation (; ). Clinical manifestations range from mild symptoms to severe complications including sepsis and death (). Despite medical advances, NEC incidence and mortality remain high, particularly among extremely low birth weight infants. Clinical observations indicate that neonatal sepsis (NS) frequently accompanies NEC development, with retrospective studies suggesting NS may serve as a risk factor (). This suggests a potential relationship between NS and NEC. However, the molecular mechanisms underlying their association remain unclear (). Current NEC diagnosis relies on nonspecific inflammatory markers and imaging examinations. These markers lack specificity and often elevate only in late disease stages, potentially causing delayed diagnosis (; ). Therefore, there is need for biomarkers with both mechanistic specificity and diagnostic sensitivity.

Existing research indicates NS and NEC may share immune dysregulation mechanisms, particularly through Toll-like receptor 4 (TLR4) pathway activation (; ). However, most studies focus on individual diseases or specific pathways, limiting knowledge of cross-disease driving genes and regulatory networks. This may impede understanding of NS-complicated NEC mechanisms and restrict therapeutic strategy development. To address these gaps, our study employs an integrated approach combining clinical analysis with bioinformatics methods. We analyzed datasets for NEC (GSE46619) and NS (GSE25504) to identify overlapping differentially expressed genes (DEGs), constructed protein-protein interaction (PPI) networks, and validated diagnostic potential using independent datasets. We also explored transcription factor-mRNA (TF-mRNA) regulatory networks.

This study aims to investigate NS as a potential NEC risk factor and explore underlying pathogenesis. We seek to identify core pathways and hub genes common to both diseases and evaluate their diagnostic utility (). Our analysis identified FPR1, S100A12, and CSF3R as potential biomarkers showing diagnostic utility in both conditions. The findings may contribute to NEC pathogenesis understanding and suggest targets for future investigation in high-risk infant identification.

2 Methods

2.1 Clinical data collection of NEC

Clinical data from 74 cases diagnosed with NEC and discharged from the Children’s Hospital of Soochow University between 1 June 2017, and 1 June 2022, were collected. These cases were matched 1:1 with non-NEC cases from the same period based on gestational age (±3 days) and weight (±100 g), resulting in the formation of NEC and non-NEC groups. The retrospective collection of case data included laboratory indicators, maternal pregnancy indicators, basic information of the infants upon admission, comorbidities, and treatment status. Exclusion criteria included: (1) clear presence of genetic metabolic diseases and chromosomal abnormalities; (2) severe congenital structural malformations; (3) refusal by the infant’s guardian to participate in this study. Diagnostic criteria and definitions: NEC diagnosis and staging were based on the modified Bell’s staging criteria (). Diagnoses of SGA, RDS, PDA, and sepsis were referenced from Avery’s Diseases of the Newborn (). Early-onset sepsis (EOS) was defined as sepsis occurring within 72 h of birth, while late-onset sepsis (LOS) was defined as sepsis occurring after 72 h of birth (). To establish the temporal sequence and minimize reverse causality, we restricted the analysis to sepsis episodes that occurred before the onset of NEC; episodes occurring after NEC onset were excluded. Maternal underlying diseases and comorbidities were all clearly diagnosed in the hospital. This study was approved by the Ethics Committee of the Children’s Hospital of Soochow University (Ethics No. 2023CS130) and conforms to the ethical standards of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from the guardians of the infants, who agreed to the use and disclosure of their clinical data.

2.2 Bioinformatics data processing

For NS, we selected the GSE25504 dataset, which contains 44 NS samples and 44 healthy control samples derived from infant blood. For NEC, we selected the GSE46619 dataset, including 5 NEC and 5 healthy control samples from intestinal tissues. Both datasets were obtained from the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/) of the National Center for Biotechnology Information (NCBI).

The selection of public datasets was guided by the following criteria: (1) human neonatal samples; (2) clearly diagnosed NEC or sepsis cases with corresponding healthy controls; (3) samples derived from clinically accessible sources (intestinal tissue or blood); (4) datasets with good data quality and standardized preprocessing; and (5) sufficient sample size to allow for differential expression analysis. Following a systematic search of the GEO database, GSE297483, GSE69686, GSE25504 and GSE46619 met all of these inclusion criteria.

For the selected transcriptome data, gene symbols were mapped according to their respective platforms. When multiple probes matched a single gene, the median expression value was used. The expression matrix was normalized using the log2 (X + 1) transformation. After quality control, quantile normalization was performed with the normalizeBetweenArrays function in the limma package to ensure comparable distributions across samples and reduce technical variability.

2.3 Pre-selection of diagnostic biomarkers

DEGs analysis was performed in the GSE46619 and GSE25504 datasets using the limma package (; ) (for differential expression analysis in RNA sequencing and microarray studies), with a cutoff criterion of P. adj.value <0.05 and |LogFC| > 1. The Benjamini–Hochberg procedure was used to adjust p-values for multiple testing. Overlapping DEGs with the same direction in NS and NEC diseases were identified using a Venn diagram tool. After intersecting the differential genes from both disease datasets, 70 overlapping genes were obtained, of which 69 were upregulated and 1 was downregulated.

2.4 GO and KEGG enrichment analysis

GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) enrichment analyses were performed for common driving genes using the clusterProfiler package (Yu et al., 2012) (an R package for comparing biological themes among gene clusters). GO was used to annotate gene biological processes, molecular functions, and cellular components. Gene pathways were annotated through KEGG. Enrichment was considered statistically significant when the P-value was less than 0.05.

2.5 Construction of protein-protein interaction networks and screening of hub genes

Overlapping genes were imported into the STRING database (http://string-db.org) () to construct a PPI network with complex interaction relationships (combined score >0.4), which was visualized in Cytoscape (version 3.8.1). Hub genes were identified by scoring differential genes using the degree method and the cytoHubba plugin (). Enrichment analysis and co-expression network analysis of hub genes were performed using the “clusterProfiler” package and GeneMANIA (http://www.genemania.org/) (Warde-Farley et al., 2010), respectively. Molecular Complex Detection (MCODE) plugin in Cytoscape was used to deconstruct functional modules, with selection criteria: degree cutoff of 2, K-core of 2, node score cutoff of 0.2, and maximum depth of 100. Datasets GSE297483 and GSE69686 were used for external validation.

2.6 Identification and diagnosis of core genes

Based on the results of external validation, these core genes were successfully identified. To evaluate the diagnostic value of each core gene and multiple genes in NEC and NS, receiver operating characteristic (ROC) curve analyses were performed separately. The area under the ROC curve (AUC) in the GSE297483 and GSE69686 datasets was used to quantify the diagnostic ability of the core genes. The “pROC” R package was used to generate ROC curves () larger AUC value indicates stronger discriminative ability of the model. In our study, all validated core genes achieved AUC values above 0.7, which suggests at least moderate discriminative ability.

2.7 Transcription factor prediction

Transcription regulatory relationships unraveled by sentence-based text mining (TRRUST) were used to obtain candidate transcription factors (TFs) regulating core genes (). This database contains rich information about TFs associated with target genes and their regulatory relationships with TFs. We constructed a TF-mRNA regulatory network and visualized it using Cytoscape. For these TFs, we performed internal validation (datasets GSE46619 and GSE25504).

2.8 Statistical analysis

Continuous variables were expressed as mean ± standard deviation or median (interquartile range) based on data distribution and compared using Student’s t-test or Mann-Whitney U test. Categorical variables were presented as frequencies (percentages) and analyzed using Chi-square test or Fisher’s exact test. Univariate logistic regression analysis was performed to identify risk factors associated with NEC development, with results presented as odds ratios (OR) with 95% confidence intervals (CI). Variables with P < 0.05 in univariate analysis were considered statistically significant. All statistical analyses were conducted using R software (version 4.4.3).

3 Results

3.1 NS as a risk factor for NEC

This study included 74 infants in the NEC group and 74 infants in the non-NEC group for comparative analysis (Table 1). The two groups showed no significant differences in baseline characteristics or perinatal factors (all P > 0.05). In terms of comorbidities, the incidence of feeding intolerance (FI) was higher in the NEC group (82.43% vs. 50.00%, P < 0.001). Laboratory indicators revealed that the platelet count (Plt) in the NEC group was significantly lower than that in the non-NEC group (184.63 vs. 243.00, P = 0.002), whereas the white blood cell count (WBC) (13.41 vs. 10.52, P = 0.040) and procalcitonin (PCT) levels (0.59 vs. 0.29, P < 0.001) were significantly higher (Table 1).

TABLE 1

VariableVariable of factorNEC_Group (n = 74)Non_NEC_Group (n = 74)StatisticP_Value
Baseline Information
Gendergirl32 (43.24%)34 (45.95%)0.0300.869
boy42 (56.76%)40 (54.05%)
Age at Admission2.00 (1.00,4.00)2.00 (2.00,4.00)−0.7020.475
BW1.46 (1.21,1.95)1.73 (1.35,2.07)−1.7330.083
SGAno48 (64.86%)52 (70.27%)0.2800.598
yes26 (35.14%)22 (29.73%)
Perinatal Information
GA224.50 (209.00,240.75)229.50 (214.00,244.50)−1.2120.226
Maternal Age30.00 (27.00,34.00)30.00 (28.00,33.00)−0.1630.872
Multiple Birthno54 (72.97%)55 (74.32%)<0.001>0.999
yes20 (27.03%)19 (25.68%)
History of Abortionno51 (68.92%)48 (64.86%)0.1200.727
yes23 (31.08%)26 (35.14%)
Mode of DeliveryVaginal Delivery19 (25.68%)22 (29.73%)0.1300.713
Cesarean Section55 (74.32%)52 (70.27%)
PROMno53 (71.62%)55 (74.32%)0.0300.853
yes21 (28.38%)19 (25.68%)
Amniotic Fluid Contaminationno62 (83.78%)63 (85.14%)<0.001>0.999
yes12 (16.22%)11 (14.86%)
Apgar Score <7 at 1 minno53 (71.62%)63 (85.14%)3.2300.072
yes21 (28.38%)11 (14.86%)
GDMno57 (77.03%)53 (71.62%)0.3200.572
yes17 (22.97%)21 (28.38%)
Preeclampsiano54 (72.97%)57 (77.03%)0.1400.704
yes20 (27.03%)17 (22.97%)
Perinatal Infectionno66 (89.19%)65 (87.84%)<0.001>0.999
yes8 (10.81%)9 (12.16%)
Gestational Hypothyroidismno69 (93.24%)68 (91.89%)<0.001>0.999
yes5 (6.76%)6 (8.11%)
Placental Abruptionno71 (95.95%)67 (90.54%)0.9700.326
yes3 (4.05%)7 (9.46%)
Comorbidities
RDSno50 (67.57%)56 (75.68%)0.8300.362
yes24 (32.43%)18 (24.32%)
FIno13 (17.57%)37 (50.00%)15.980<0.001
yes61 (82.43%)37 (50.00%)
Neonatal Anemiano7 (9.46%)21 (28.38%)7.4400.006
yes67 (90.54%)53 (71.62%)
Neonatal Asphyxiano53 (71.62%)60 (81.08%)1.3500.246
yes21 (28.38%)14 (18.92%)
ICHno52 (70.27%)60 (81.08%)1.8000.180
yes22 (29.73%)14 (18.92%)
BPDno67 (90.54%)67 (90.54%)<0.001>0.999
yes7 (9.46%)7 (9.46%)
PDAno42 (56.76%)49 (66.22%)1.0300.311
yes32 (43.24%)25 (33.78%)
Hypoglycemiano55 (74.32%)61 (82.43%)1.0000.318
yes19 (25.68%)13 (17.57%)
Neonatal Pneumoniano16 (21.62%)14 (18.92%)0.0400.838
yes58 (78.38%)60 (81.08%)
Respiratory Failureno54 (72.97%)52 (70.27%)0.0300.855
yes20 (27.03%)22 (29.73%)
Apneano48 (64.86%)50 (67.57%)0.0300.862
yes26 (35.14%)24 (32.43%)
Neonatal Sepsisno29 (39.19%)49 (66.22%)9.7900.002
yes45 (60.81%)25 (33.78%)
Laboratory Indicators
ALT4.50 (3.00,7.15)4.30 (2.62,6.47)1.2830.200
AST47.70 (32.95,75.38)49.05 (30.52,69.40)0.5620.576
ALP199.00 (160.25,273.50)201.50 (147.50,248.25)0.4830.630
Plt184.63 (123.94,258.19)243.00 (194.25,285.25)−3.1260.002
WBC13.41 (9.95,19.77)10.52 (8.59,16.38)2.0560.040
PCT0.59 (0.27,5.01)0.29 (0.18,0.92)3.632<0.001
CRP29.95 (25.50,34.03)5.63 (3.16,7.09)10.500<0.001
Blood Cultureno53 (71.62%)73 (98.65%)19.270<0.001
yes21 (28.38%)1 (1.35%)
Treatment Status
Mechanical Ventilation Useno27 (36.49%)38 (51.35%)2.7400.098
yes47 (63.51%)36 (48.65%)
Dual Antibiotic Useno54 (72.97%)64 (86.49%)3.3900.066
yes20 (27.03%)10 (13.51%)
Blood Product Transfusionno10 (13.51%)24 (32.43%)6.4500.011
yes64 (86.49%)50 (67.57%)
Probiotic Useno26 (35.14%)34 (45.95%)1.3700.241
yes48 (64.86%)40 (54.05%)
Hospital Stay Duration50.00 (34.00,65.25)29.50 (17.00,49.00)4.355<0.001

Comparison of baseline characteristics and clinical indicators between NEC and non-NEC groups.

Abbreviations: NEC, neonatal necrotizing enterocolitis; BW, birth weight (kg); SGA, small for gestational age; GA, gestational age (days); PROM, premature rupture of membranes; GDM, gestational diabetes mellitus; RDS, respiratory distress syndrome; FI, feeding intolerance; ICH, intracranial hemorrhage; BPD, bronchopulmonary dysplasia; PDA, patent ductus arteriosus; ALT, alanine aminotransferase (U/L); AST, aspartate aminotransferase (U/L); ALP, alkaline phosphatase (U/L); Plt, platelet count (×109/L); WBC, white blood cell count (×109/L); PCT, procalcitonin (ng/mL); CRP, C-reactive protein (mg/L).

Among the 70 infants diagnosed with sepsis, 45 (64.3%) developed NEC while 25 (35.7%) did not. Notably, early-onset sepsis was significantly more prevalent in the NEC group compared to the non-NEC group (57.78% vs. 4.00%, P < 0.001), while late-onset sepsis showed the opposite pattern (42.22% vs. 96.00%) (Table 2). Additionally, positive blood cultures were more frequently observed in sepsis patients who developed NEC (46.67% vs. 4.00%, P < 0.001).

TABLE 2

VariableVariable of factorNEC_Group (n = 45)Non_NEC_Group (n = 25)StatisticP-value
Gendergirl17 (37.78%)8 (32.00%)0.050.8235
boy28 (62.22%)17 (68.00%)
Age at Admission2.00 (1.00,5.00)3.00 (2.00,7.00)−0.85190.3878
BW1.32 (1.15,1.85)1.41 (1.20,1.87)−0.17770.8637
SGAno30 (66.67%)18 (72.00%)0.040.8478
yes15 (33.33%)7 (28.00%)
GA217.00 (207.00,236.00)221.00 (207.00,231.00)0.05520.9609
ALT4.40 (2.60,7.00)4.90 (3.60,6.60)−0.44740.6589
AST52.00 (31.50,86.30)52.30 (35.90,68.80)−0.04290.9707
ALP192.00 (150.00,251.00)204.00 (171.00,258.00)−0.87640.3841
Plt169.00 (111.01,239.28)248.00 (188.00,286.00)−2.60460.0094
WBC13.41 (9.41,18.83)12.30 (9.45,20.62)0.20220.8445
PCT2.78 (0.33,11.38)0.56 (0.33,2.61)1.61790.1069
CRP30.98 (25.49,35.04)5.63 (3.55,6.69)6.8946<0.001
Sepsis classificationeos26 (57.78%)1 (4.00%)17.41<0.001
los19 (42.22%)24 (96.00%)
Blood Cultureno24 (53.33%)24 (96.00%)11.670.0006
yes21 (46.67%)1 (4.00%)

Comparison of early-onset versus late-onset sepsis in NEC and Non-NEC groups.

Abbreviations: NEC, neonatal necrotizing enterocolitis; BW, birth weight (kg); SGA, small for gestational age; GA, gestational age (days); ALT, alanine aminotransferase (U/L); AST, aspartate aminotransferase (U/L); ALP, alkaline phosphatase (U/L); Plt, platelet count (×109/L); WBC, white blood cell count (×109/L); PCT, procalcitonin (ng/mL); CRP, C-reactive protein (mg/L); Eos, Early-onset sepsis; Los, Late-onset sepsis.

In summary, compared to non-NEC infants, those with NEC exhibited more severe systemic inflammatory responses (elevated WBC, PCT, and C-reactive protein (CRP), and decreased Plt), a higher incidence of FI, anemia, and sepsis, increased transfusion requirements, and longer hospital stays. We performed univariate logistic regression analysis for NEC based on statistically significant variables, and the forest plot results indicated that FI, neonatal anemia, blood product use, and NS were risk factors, while Plt levels approached being a protective factor (Figure 1A).

FIGURE 1

3.2 Identification and functional analysis of overlapping DEGs

The study flowchart is illustrated in Figure 1B. A total of 204 and 1420 DEGs were identified from the GSE25504 and GSE46619 datasets, respectively (Figures 2A,B). In the intersection of these datasets, 70 overlapping DEGs with concordant directions of change were identified (69 upregulated and 1 downregulated) (Figures 2C,D). The complete list of DEGs is available as supplementary data, specifically in Supplementary Tables S1-S3. To investigate potential biological functions, GO enrichment analysis and KEGG pathway analysis were conducted on the overlapping DEGs using R software (Figures 2E,F). The results of the GO analysis revealed significant enrichment in the biological process (BP) terms, including cytokine-mediated immune response, leukocyte migration, and positive regulation of immune effector processes. In the cellular component (CC) terms, significant enrichment was observed in extracellular exosomes, specific granule membranes, and granule lumens. Furthermore, in the molecular function (MF) terms, significant enrichment was noted in cytokine receptor binding, immune receptor activity, and integrin binding (Supplementary Tables S4, S5). Additionally, pathways related to pertussis, the tumor necrosis factor (TNF) signaling pathway, cytokine-cytokine receptor interaction, rheumatoid arthritis, acute myeloid leukemia, inflammatory bowel disease, glucose metabolism, and tuberculosis were significantly enriched in the KEGG analysis. These findings suggest that pathways associated with immune response, cytokine signaling, and infection may play crucial roles in the pathogenesis of NS and NEC.

FIGURE 2

3.3 PPI network construction and subnetwork screening

The PPI network contained 43 nodes and 263 interacting pairs (Supplementary Tables S6). An important subnetwork within the hub gene network was screened using the MCODE module in Cytoscape, which included 14 nodes and 80 interacting pairs (Supplementary Tables S7). These 14 nodes were IL1RN, FPR1, FPR2, HCK, S100A12, CSF3R, IL1B, FCGR1A, FCER1G, CD163, ITGAM, SPI1, MMP9, and C5AR1, with specific scores detailed in Supplementary Tables S8.

3.4 Hub gene selection and enrichment analysis

Hub genes were identified using the degree algorithm in the CytoHubba plugin, as detailed in Supplementary Tables S9. Figure 3A presents the decomposition diagram of the PPI network alongside the network constructed from the hub genes. A total of 10 hub genes were identified, including MMP9, FPR1, FCER1G, CD163, S100A12, ITGAM, SPI1, IL1RN, IL1B, and CSF3R. The interaction network of these genes was constructed using the GeneMANIA database, revealing significant enrichment in functions related to innate immunity and inflammation, such as tertiary granule formation, humoral immune response, secretory granule membrane, reactive oxygen species metabolic process, positive regulation of defense response, ficolin-1-rich granule, and NAD(P)H oxidoreductase activity (Figure 3B). Subsequent enrichment analysis indicated significant enrichment in immune cell chemotaxis and activation, as well as receptor signaling, particularly in biological processes (e.g., neutrophil/granulocyte chemotaxis, migration, activation, and heterotypic cell adhesion), cellular components (e.g., ficolin-1-rich granules and their membranes, tertiary granules and their membranes, endocytic vesicles and their membranes, lysosomal membranes, integrin complexes), molecular functions (e.g., immune receptor activity, receptor for advanced glycation end products (RAGE) binding, interleukin-1 receptor binding, cytokine binding, integrin binding, complement component C3b binding, IgG binding, complement receptor activity), and KEGG pathways (e.g., cytokine-cytokine receptor interaction, leukocyte transendothelial migration, IL-17 signaling pathway, Staphylococcus aureus infection, tuberculosis, pertussis, leishmaniasis, type 1 diabetes) (Figures 3C,D; Supplementary Tables S10, S11).

FIGURE 3

3.5 Diagnostic efficacy of core genes

To identify reliable core genes, we conducted external validation on the selected genes. In the NEC dataset (GSE297483), only the expression levels of FPR1, S100A12, and CSF3R were significantly elevated compared to the control group (Figure 4A), while no statistical differences were observed for the other genes. In NS samples, nine genes had significantly higher expression levels than the control group, while IL1B showed no significant difference (GSE69686, Figure 4B). Consequently, we identified three core genes: FPR1, S100A12, and CSF3R. Subsequently, we generated ROC curves using external validation datasets to further assess the diagnostic value of these validated core genes. In the NEC-related validation dataset, the AUC values for FPR1, S100A12, and CSF3R were 0.762, 0.762, and 0.746, respectively (Figures 4C–E). Furthermore, in the NS-related validation dataset, the AUC values for all validated core genes exceeded 0.7, measuring 0.723, 0.813, and 0.807, respectively (Figures 4G–I).

FIGURE 4

3.6 Integrated TF-mRNA network

The TRRUST database provides insights into the regulatory relationships between transcription factors and their target genes, elucidating their interactions. In this study, we utilized transcription factor binding site information from TRRUST to identify key transcription factors and target genes associated with NEC and NS. We identified a total of 35 associations involving 14 transcription factors (SPI1, ETS2, CEBPA, NFKBIA, JUN, SIRT1, FOS, CEBPB, RELA, NFKB1, ETS1, STAT1, STAT3, and SP1) and 6 core genes (IL1B, ITGAM, CSF3R, CD163, MMP9, and IL1RN), with specific regulatory relationships detailed in Supplementary Tables S12. Based on these findings, we constructed a transcription factor-messenger RNA regulatory network using Cytoscape software (Figure 5A) and validated it against the NEC and NS datasets. By analyzing gene expression data from the GSE46619 (NEC) and GSE25504 (NS) datasets, we confirmed the expression changes of these transcription factors in both conditions. Validation results indicated that several transcription factors exhibited significant expression changes in NEC and NS, further supporting their putative regulatory roles in these diseases (Figures 5B,C). We distinguished mRNA and TFs through different shapes and colors, effectively illustrating this regulatory network and suggesting that these TFs may play crucial roles in the pathological processes of NEC and NS.

FIGURE 5

4 Discussion

This study explored the potential relationship between neonatal sepsis and NEC development through integrated clinical and bioinformatics approaches. Our clinical analysis suggests that sepsis may serve as a risk factor for NEC, with affected infants demonstrating heightened inflammatory responses and increased healthcare complexity. The bioinformatics investigation identified shared molecular signatures between these conditions, particularly involving genes related to neutrophil function and inflammatory processes (FPR1, S100A12, CSF3R). These findings suggest that common inflammatory pathways may underlie the clinical association between sepsis and NEC, providing insights into potential mechanisms linking these conditions in neonatal populations.

Our clinical data suggest that sepsis may serve as a risk factor for NEC, consistent with previous observations. Early-onset sepsis was more prevalent in NEC patients, suggesting that early inflammatory insults may predispose to intestinal complications, consistent with known effects of systemic inflammation on gut barrier function. The pathophysiological connection may involve several mechanisms. Neonatal gut microbiota dysbiosis can compromise mucosal barrier function, facilitating pathogen colonization and subsequent systemic inflammation (; ). Sepsis-induced inflammatory responses, particularly through TLR4 pathway activation, may exacerbate intestinal immune imbalance and epithelial damage (). Premature infants appear particularly vulnerable due to insufficient expression of immune regulatory factors such as TOLLIP and SIGIRR (). The clinical presentation in our NEC cohort reflected these inflammatory processes, with elevated inflammatory markers and thrombocytopenia correlating with disease severity. Additional factors such as neonatal anemia and transfusion requirements may further contribute to intestinal injury through tissue hypoxia and transfusion-associated inflammatory responses (). These overlapping systemic features between NEC and NS provided the rationale for our bioinformatics investigation of shared molecular mechanisms.

The identification of 70 overlapping DEGs with conserved expression patterns between NS and NEC datasets suggests potential shared pathological mechanisms. The enrichment of these genes in immune-related pathways, particularly cytokine signaling and leukocyte activation, may reflect the characteristic immune dysregulation observed in both conditions. This pattern appears consistent with known features of neonatal immune immaturity (), including reduced monocyte sensitivity to TLR ligands and impaired dendritic cell IL-12p70 secretion (). The mechanistic implications of these findings deserve consideration. Cytokine-cytokine receptor interactions, particularly involving TNF-α and IL-17 pathways, may contribute to NF-κB activation and subsequent intestinal barrier dysfunction through downregulation of tight junction proteins (). The involvement of inflammatory amplification mechanisms, including sympathetic nerve-mediated immune cell infiltration, could potentially explain the progression to intestinal necrosis characteristic of NEC (). These observations suggest that select overlapping DEGs, warrant investigation as potential biomarkers for both conditions.

The PPI network analysis suggests that neutrophil-related genes (FPR1, S100A12, CSF3R, ITGAM) and inflammatory mediators (IL1B, MMP9, IL1RN) may function coordinately in sepsis-complicated NEC. These genes appear to participate in processes involving damage sensing, chemotactic recruitment, and cellular activation. During the inflammatory amplification phase, IL-1β may induce pro-inflammatory factor expression through NF-κB pathway activation, with insufficient IL1RN expression potentially exacerbating this response (). MMP9 could disrupt tight junction proteins and upregulate IL-8 signaling, forming a positive feedback loop that compromises barrier function (). Clinical observations supporting this model include the positive correlation between neutrophil dysfunction and NEC surgical risk (), and the association between reactive oxygen species (ROS) levels and epithelial apoptosis rates in NEC tissues (). This integrated model suggests that bacterial infection may trigger FPR1/CSF3R signaling, leading to neutrophil infiltration and subsequent IL-1β/MMP9 release, ultimately resulting in intestinal barrier disruption and bacterial translocation (Wenceslau et al., 2019; ). While this framework provides mechanistic insights into sepsis-NEC progression, experimental validation remains necessary to confirm these proposed relationships.

The consistent upregulation of FPR1, S100A12, and CSF3R in both NEC and NS validation cohorts highlights their potential as clinically relevant biomarkers. Among these, S100A12 is particularly promising. Studies have demonstrated that serum S100A12 is a highly sensitive and specific biomarker for neonatal sepsis, outperforming conventional markers like CRP in early detection (). Furthermore, fecal S100A12 levels are significantly elevated 4–10 days before the clinical onset of severe NEC, offering a critical window for early risk assessment and intervention (). S100A12 may contribute to inflammation through TLR4/NF-κB signaling, potentially associated with intestinal mucosal changes ().

As a primary sensor for bacterial and mitochondrial N-formyl peptides, FPR1 orchestrates neutrophil chemotaxis and activation, a process central to the pathogenesis of both infection-driven sepsis and injury-associated NEC (). While essential for pathogen clearance, this FPR1-driven neutrophil response can also inflict severe collateral tissue damage, making it a double-edged sword in the fragile neonatal environment (). Therefore, FPR1 not only holds potential as an early biomarker for inflammatory crises but also represents a promising therapeutic target for modulating the destructive hyper-inflammation characteristic of these devastating neonatal diseases.

CSF3R regulates neutrophil proliferation, differentiation, and survival through granulocyte colony-stimulating factor (G-CSF) signaling (). During neonatal infections, increased CSF3R expression is associated with enhanced innate immune responses. However, dysregulated CSF3R signaling may lead to the release of immature neutrophils, which could reduce microbial clearance efficiency and contribute to tissue damage. These findings suggest that CSF3R might function both as an indicator of inflammatory intensity and a candidate target for therapies aimed at improving neutrophil function.

Our transcription factor analysis identified SPI1, NFKB1, and JUN as potential regulatory factors in the NS-NEC pathway, though the mechanistic relationships require careful interpretation. SPI1 may influence CSF3R expression, potentially affecting neutrophil function through JAK/STAT signaling (Zhang et al., 2024). The NFKB1-IL1B regulatory relationship suggests possible involvement in inflammatory amplification, as NF-κB signaling has been implicated in cytokine production and intestinal barrier dysfunction (). JUN appears to regulate MMP9 expression, which could contribute to tissue remodeling processes, though the specific role in neonatal intestinal pathology remains to be fully characterized (Zhu et al., 2025). While these transcription factors may work collectively to influence immune cell activation and tissue responses, the extent of their contribution to sepsis-complicated NEC pathogenesis requires further investigation. The complex interplay between these regulatory networks suggests that therapeutic targeting of individual pathways may have limited efficacy, highlighting the need for more comprehensive approaches to understanding and treating these conditions.

5 Limitations

This study has certain limitations that need to be addressed in future research. First, as a retrospective study, although the sample size is large and externally validated, potential biases may still exist, requiring further validation through prospective studies. Second, the identified core genes have not been functionally validated in humans. Although their functions have been predicted through bioinformatics, their specific roles in NEC and NS still require in vitro cell experiments and in vivo animal model validation. Finally, the study mainly focused on gene expression and bioinformatics analysis. The specific molecular mechanisms by which core genes regulate immune responses still need to be elucidated through detailed molecular biology experiments.

6 Conclusion

This study suggests that neonatal sepsis may serve as a risk factor for NEC development through shared inflammatory pathways. Our integrated analysis identified overlapping gene expression patterns between NS and NEC, with FPR1, S100A12, and CSF3R showing potential diagnostic utility across both conditions. These genes appear to participate in inflammatory processes involving immune-cell recruitment and activation, possibly mediated by transcriptional networks including SPI1, NFKB1, and JUN. While these computational findings provide insights into potential common mechanisms between NS and NEC, prospective clinical validation and functional experiments are necessary to confirm these relationships and assess their therapeutic implications.

Statements

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm.nih.gov/, GSE25504 https://www.ncbi.nlm.nih.gov/, GSE46619 https://www.ncbi.nlm.nih.gov/, GSE297483 https://www.ncbi.nlm.nih.gov/, GSE69686.

Ethics statement

The studies involving humans were approved by Children’s Hospital of Soochow University, China. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants’ legal guardians/next of kin.

Author contributions

XL: Methodology, Writing – original draft. WS: Investigation, Funding acquisition, Writing – review and editing. JB: Data curation, Formal Analysis, Writing – review and editing, Software. YL: Writing – review and editing, Data curation, Conceptualization. XJ: Data curation, Investigation, Project administration, Writing – review and editing, Formal Analysis. XZ: Methodology, Validation, Funding acquisition, Resources, Writing – review and editing.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by National Natural Science Foundation of China (Grant No. 82271741), Jiangsu Provincial Health and Family Planning Commission Medical Research Project (Grant No. ZD2021013), Suzhou Health Talent Program (Grant No. GSWS2022055), Soochow University Translational Platform Program (Grant No. ML13101523), “Suiyuan” Clinical Research Program (Grant No. SY003), Academic Degree and Postgraduate Education Reform Project of Jiangsu Province (Grant No. SJCX25_1803) and 2025 Student Intramural Research Project of Children’s Hospital of Soochow University (Grant No. B07).

Acknowledgments

We thank the children and guardians who participated in this study. We also acknowledge the contributors who made their datasets publicly available.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmolb.2025.1662343/full#supplementary-material

Glossary

  • NEC

    Necrotizing Enterocolitis

  • NS

    Neonatal Sepsis

  • EOS

    Early-onset sepsis

  • LOS

    Late-onset sepsis

  • DEGs

    Differentially Expressed Genes

  • PPI

    Protein-Protein Interaction

  • GO

    Gene Ontology

  • KEGG

    Kyoto Encyclopedia of Genes and Genomes

  • TF

    Transcription Factor

  • ROC

    Receiver Operating Characteristic

  • AUC

    Area Under the Curve

  • CRP

    C-reactive protein

  • PCT

    Procalcitonin

  • WBC

    White Blood Cell Count

  • Plt

    Platelet Count

  • SGA

    Small for Gestational Age

  • RDS

    Respiratory Distress Syndrome

  • PDA

    Patent Ductus Arteriosus

  • FI

    Feeding Intolerance

  • ICH

    Intracranial Hemorrhage

  • BPD

    Bronchopulmonary Dysplasia

  • ALT

    Alanine Aminotransferase

  • AST

    Aspartate Aminotransferase

  • ALP

    Alkaline Phosphatase

  • BP

    Biological Process

  • CC

    Cellular Component

  • MF

    Molecular Function

  • TNF

    Tumor necrosis factor

  • TLR4

    Toll-like receptor 4

  • ROS

    Reactive Oxygen Species

  • RAGE

    Receptor for advanced glycation end products

  • G- CSF

    Granulocyte Colony-stimulating Factor

  • MCODE

    Molecular Complex Detection

References

Summary

Keywords

neonatal sepsis, necrotizing enterocolitis, neutrophil chemotaxis, diagnostic biomarkers, transcriptional regulatory network

Citation

Liu X, Sun W, Bian J, Li Y, Jin X and Zhu X (2025) Clinical association and potential molecular mechanisms of neonatal sepsis and necrotizing enterocolitis. Front. Mol. Biosci. 12:1662343. doi: 10.3389/fmolb.2025.1662343

Received

09 July 2025

Accepted

22 September 2025

Published

02 October 2025

Volume

12 - 2025

Edited by

Weiguo Chen, University of Illinois Chicago, United States

Reviewed by

Nitin Kamble, University of Cincinnati Medical Center, United States

Haiyan Guo, Shanghai Jiao tong University School of Medicine, China

Updates

Copyright

*Correspondence: Xueping Zhu,

† These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics